GRI BIO INC (GRI) Fundamental Analysis & Valuation

NASDAQ:GRI • US3622AW5029

2.75 USD
+0.25 (+10%)
At close: Mar 10, 2026
2.81 USD
+0.06 (+2.18%)
Pre-Market: 3/11/2026, 8:00:38 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GRI. GRI was compared to 519 industry peers in the Biotechnology industry. The financial health of GRI is average, but there are quite some concerns on its profitability. GRI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. GRI Profitability Analysis

1.1 Basic Checks

  • GRI had negative earnings in the past year.
  • GRI had a negative operating cash flow in the past year.
  • In the past 5 years GRI always reported negative net income.
  • GRI had a negative operating cash flow in each of the past 5 years.
GRI Yearly Net Income VS EBIT VS OCF VS FCFGRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • GRI has a worse Return On Assets (-137.96%) than 82.47% of its industry peers.
  • GRI's Return On Equity of -199.00% is on the low side compared to the rest of the industry. GRI is outperformed by 67.82% of its industry peers.
Industry RankSector Rank
ROA -137.96%
ROE -199%
ROIC N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRI Yearly ROA, ROE, ROICGRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

1.3 Margins

  • GRI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRI Yearly Profit, Operating, Gross MarginsGRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. GRI Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for GRI has been increased compared to 1 year ago.
  • GRI has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for GRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRI Yearly Shares OutstandingGRI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K
GRI Yearly Total Debt VS Total AssetsGRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • GRI has an Altman-Z score of -11.19. This is a bad value and indicates that GRI is not financially healthy and even has some risk of bankruptcy.
  • GRI has a Altman-Z score of -11.19. This is in the lower half of the industry: GRI underperforms 75.14% of its industry peers.
  • There is no outstanding debt for GRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.19
ROIC/WACCN/A
WACCN/A
GRI Yearly LT Debt VS Equity VS FCFGRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • GRI has a Current Ratio of 3.25. This indicates that GRI is financially healthy and has no problem in meeting its short term obligations.
  • GRI's Current ratio of 3.25 is on the low side compared to the rest of the industry. GRI is outperformed by 62.04% of its industry peers.
  • GRI has a Quick Ratio of 3.25. This indicates that GRI is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.25, GRI is doing worse than 60.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.25
GRI Yearly Current Assets VS Current LiabilitesGRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GRI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.65% over the past year.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-582950%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.89% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.68%
EPS Next 2Y39.15%
EPS Next 3Y24.89%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRI Yearly Revenue VS EstimatesGRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 20K 40K 60K 80K
GRI Yearly EPS VS EstimatesGRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2024 2025 2026 2027 2028 -10K -20K -30K -40K -50K

More info and screens

Find the best growth stocksShow best growing peers

1

4. GRI Valuation Analysis

4.1 Price/Earnings Ratio

  • GRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRI Price Earnings VS Forward Price EarningsGRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRI Per share dataGRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GRI's earnings are expected to grow with 24.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.15%
EPS Next 3Y24.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRI Dividend Analysis

5.1 Amount

  • No dividends for GRI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRI Fundamentals: All Metrics, Ratios and Statistics

GRI BIO INC

NASDAQ:GRI (3/10/2026, 8:00:01 PM)

Premarket: 2.81 +0.06 (+2.18%)

2.75

+0.25 (+10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners0.15%
Inst Owner Change-60.13%
Ins Owners0%
Ins Owner Change0%
Market Cap3.99M
Revenue(TTM)N/A
Net Income(TTM)-11.96M
Analysts80
Price Target656.88 (23786.55%)
Short Float %N/A
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-165.43%
Min EPS beat(2)-294.58%
Max EPS beat(2)-36.27%
EPS beat(4)1
Avg EPS beat(4)-92.4%
Min EPS beat(4)-294.58%
Max EPS beat(4)0.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)528.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2159.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-2660.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-194.93
EYN/A
EPS(NY)-49.35
Fwd EYN/A
FCF(TTM)-5.94
FCFYN/A
OCF(TTM)-5.94
OCFYN/A
SpS0
BVpS4.14
TBVpS4.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -137.96%
ROE -199%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.25
Altman-Z -11.19
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-582950%
EPS Next Y74.68%
EPS Next 2Y39.15%
EPS Next 3Y24.89%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.79%
EBIT Next 3Y-23.71%
EBIT Next 5Y-20.69%
FCF growth 1Y4.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.22%
OCF growth 3YN/A
OCF growth 5YN/A

GRI BIO INC / GRI FAQ

What is the ChartMill fundamental rating of GRI BIO INC (GRI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GRI.


What is the valuation status of GRI BIO INC (GRI) stock?

ChartMill assigns a valuation rating of 1 / 10 to GRI BIO INC (GRI). This can be considered as Overvalued.


Can you provide the profitability details for GRI BIO INC?

GRI BIO INC (GRI) has a profitability rating of 0 / 10.